Palo Alto Networks Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Palo Alto Networks Inc. on November 15, 2024. The report supplements the definitive proxy statement filed on October 29, 2024, for the Company's 2024 Annual Meeting of Shareholders scheduled for December 10, 2024. The filing primarily addresses Item 8.01 (Other Events) regarding recent equity award grants and plan status.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on equity compensation plan data as of November 10, 2024:
- Total Stock Options Outstanding: 4,181,136
- Weighted-Average Exercise Price: $65.30 per share
- Weighted-Average Remaining Duration: 0.97 years
- Total Restricted Stock Units (including PSUs) Outstanding: 14,636,462
- Shares Available for Grant (2021 Plan): 11,505,724
Material Changes
On November 10, 2024, the Company granted additional equity awards totaling 1,467,999 shares under the 2021 Equity Incentive Plan. Following these grants, 11,505,724 shares remained available for future grants under the 2021 Plan. Additionally, 18,817,598 shares are currently subject to outstanding awards across the 2012 and 2021 Equity Incentive Plans.
Guidance, Outlook, and Risks
Expected Grants: Prior to the Annual Meeting, the Company expects to grant additional restricted stock units for up to approximately 23,397 shares and performance stock units with a maximum potential payout of up to approximately 338,607 shares, subject to board or committee approval.
Forward-Looking Statements: The filing contains forward-looking statements regarding future expectations. Actual results may differ materially due to risks and uncertainties discussed in the "Risk Factors" section of the 2024 Annual Report on Form 10-K. The Company does not assume an obligation to update these statements.
Investor Verification Checklist
- Verify the total number of shares available for grant under the 2021 Plan post-November 10 grants (11,505,724).
- Confirm the weighted-average exercise price of outstanding stock options ($65.30) against current market prices to assess dilution potential.
- Review the 2024 Annual Report on Form 10-K for detailed risk factors referenced in this filing.
- Monitor the outcome of the December 10, 2024 Annual Meeting regarding the approval of expected additional grants.